Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification

por Sang, Yun Beom, Kim, Gwangil, Hwang, Sohyun, Kang, Haeyoun, Chon, Hong Jae
Publicado 2023

Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach

por Kim, Chang-Gon, Sang, Yun-Beom, Lee, Ji-Hyun, Chon, Hong-Jae
Publicado 2021

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma

por Kim, Youngun, Yang, Hannah, Lee, Won Suk, Cheon, Jaekyung, Sang, Yun Beom, Kang, Beodeul, Chon, Hong Jae, Kim, Chan
Publicado 2023

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges

por Sang, Yun Beom, Kim, Joo-Hang, Kim, Chang-Gon, Hong, Min Hee, Kim, Hye Ryun, Cho, Byoung Chul, Lim, Sun Min
Publicado 2022

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma

por Sang, Yun Beom, Yang, Hannah, Lee, Won Suk, Lee, Seung Joon, Kim, Seul-Gi, Cheon, Jaekyung, Kang, Beodeul, Kim, Chang Woo, Chon, Hong Jae, Kim, Chan
Publicado 2022

Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis

por Cheon, Jaekyung, Lee, Choong-kun, Sang, Yun Beom, Choi, Hye Jin, Kim, Min Hwan, Ji, Jun Ho, Ko, Kwang Hyun, Kwon, Chang-Il, Kim, Dae Jung, Choi, Sung Hoon, Kim, Chan, Kang, Beodeul, Chon, Hong Jae
Publicado 2021